EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men

Scott R Bauer, Stacey A Kenfield, Akinyemi Oni-Orisan, Michael G Shlipak, Kaiwei Lu, Natalie Rios, Robert Pearce, Joseph Harmon, Charles E McCulloch, Liusheng Huang, Michael A Steinman, Benjamin N Breyer

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.21639 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Scott R Bauer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Medicine, University of California, San Francisco. Hauptthemen laut MEDLINE: Deprescriptions, Lower Urinary Tract Symptoms, Prostatic Hyperplasia, Tamsulosin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Tamsulosin is the most common treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH). The ability of N-of-1 deprescribing trials to identify who may benefit from discontinuing chronic tamsulosin therapy is unknown.

Objective

To determine if N-of-1 deprescribing trials can identify older men who are receiving minimal benefit from tamsulosin therapy for LUTS. Design, Setting, and Participants Double-blind, placebo-controlled, multiple crossover (N-of-1) randomized clinical trial conducted at a single academic urology department between September 2021 and July 2022. After a 1-week placebo run-in, men aged 55 to 80 years who were continuous users of tamsulosin for at least 12 months to treat symptoms of BPH were randomly assigned to 2 blocks of 2-week treatment periods alternating tamsulosin and placebo, separated by 1-week washout periods. Data were analyzed from November 2022 to October 2024.

Intervention

Tamsulosin, dosed at either 0.4 mg or 0.8 mg, vs matching placebo. Main Outcomess and Measures The efficacy outcome was daily American Urological Association Symptom Index (AUASI) with an adapted recall period of 24 hours. Effect size was categorized based on the upper bound of the individual 95% CI for the tamsulosin-placebo difference in daily AUASI: minimal or no (≥0), moderate (>−6.0 to <0), or strong (≤−6.0) effect. Adverse drug events were assessed daily as a secondary outcome. Demographics, clinical characteristics, and attitudes toward deprescribing were assessed at baseline.

Results

Among the 31 participants enrolled, the mean (SD) age was 68.8 (5.7) years. Of 30 participants who attempted the full N-of-1 protocol, 11 (36.7%) had minimal or no tamsulosin effect, 11 (36.7%) had moderate effect, 4 (13.3%) had strong effect, and 4 (13.3%) did not tolerate the 1-week placebo run-in due to worsening symptoms. Based on a mean (SD) of 54 (3) daily LUTS assessments per participant, individual-level estimated mean difference in daily AUASI between tamsulosin and placebo ranged from −10.9 (95% CI, −12.6 to −9.1) to 2.1 (95% CI, 0.4 to 3.9). The group-level mean difference in daily AUASI was −2.96 (95% CI, −4.37 to −1.54). Conclusions and Relevance In this randomized N-of-1 clinical trial of tamsulosin deprescribing, treatment response was heterogeneous. The findings suggest that 1 in 3 older men who had minimal symptomatic benefit from tamsulosin may be high-priority candidates for deprescribing. Trial Registration ClinicalTrials.gov Identifier: NCT05415748

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeprescriptionsLower Urinary Tract SymptomsProstatic HyperplasiaTamsulosinAgedAged, 80 and overHumansMaleMiddle AgedCross-Over StudiesDouble-Blind MethodTreatment OutcomeSingle-Case Studies as Topic

Substanzen

Tamsulosin

Autor:innen und Institutionen

  • Division of General Internal Medicine, Department of Medicine, University of California, San Francisco.
  • Department of Urology, University of California, San Francisco.
  • San Francisco VA Healthcare System, San Francisco, California.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco.
  • Department of Clinical Pharmacy, University of California, San Francisco.
  • Division of Geriatrics, Department of Medicine, University of California, San Francisco.

Zitieren

APA

Bauer, S. R., Kenfield, S. A., Oni-Orisan, A., Shlipak, M. G., Lu, K., Rios, N., Pearce, R., Harmon, J., McCulloch, C. E., Huang, L., Steinman, M. A., & Breyer, B. N. (2026). Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.21639

Vancouver

Bauer SR, Kenfield SA, Oni-Orisan A, Shlipak MG, Lu K, Rios N, et al. Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.21639

BibTeX
@article{Bauer2026,
  author = {Bauer, Scott R and Kenfield, Stacey A and Oni-Orisan, Akinyemi and Shlipak, Michael G and Lu, Kaiwei and Rios, Natalie and Pearce, Robert and Harmon, Joseph and McCulloch, Charles E and Huang, Liusheng and Steinman, Michael A and Breyer, Benjamin N},
  title = {Tamsulosin Deprescribing for Lower Urinary Tract Symptoms in Older Men},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.21639}
}
Kostenlos starten →